Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07309380Phase 3Not Yet Recruiting

Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

Role: lead

NCT06505928Phase 2Active Not Recruiting

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

Role: lead

NCT04426968Phase 2Completed

A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Role: lead

NCT05244057Phase 2Completed

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Role: lead

NCT05827146Phase 2Completed

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Role: lead

NCT04662164Phase 1Withdrawn

A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin

Role: lead

NCT02612506Phase 1Completed

Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers

Role: lead

NCT03023787Phase 1Completed

Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

Role: lead

All 8 trials loaded